Chief Executive Officer Dr Howie McKibbon will present to institutional investors at today’s Canaccord Drug and Device Healthcare Conference in Noosa. For the balance of the week, Canaccord Genuity will host a Botanix investor roadshow.
The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q1 FY2026 have been released. Quarter over quarter, total prescriptions for Sofdra® (sofpironium) increased 50% to 20,418 as operating cash outflow decreased 54% to $13.1 million. Net revenue was $7.1 million.
Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on Monday 20 October at 11.00 am AEDT / 8.00 am AWST for an important update.
Participants must pre-register: Click here
Botanix Executive Chairman Vince Ippolito will be a featured presenter on Tuesday, 9 September at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US). This conference attracts institutional fund managers from around the world and some of the most promising global growth companies, including those in the healthcare and life sciences sectors.
Botanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. Dongwha is a sublicensee of Botanix’s Japanese partner, Kaken Pharmaceutical Co. Ltd.
Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive range of prescription and over-the-counter products.
The Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability.
Botanix welcomes Patricia Walker, MD, PhD, to the Board. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies and the insights of a working dermatologist. She has led drug development for numerous key dermatology products, including Sofdra™ (sofpironium), from a preclinical asset to Phase 3 before its acquisition by Botanix.
Botanix Chief Executive Officer Dr Howie McKibbon will be a featured presenter at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, which attracts institutional fund managers from around the world, and some of the most promising global growth companies, including those in the healthcare and life sciences sectors, will present during the event.
The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q4 FY2025 have been released. During the quarter, Botanix raised A$40m in capital, established a loan facility of up to the euro equivalent of US$30 million, and ended the quarter with A$64.9m cash. With operating costs stable and revenues expected to rise, Botanix is well funded to support Sofdra™ (sofpironium) to profitability.
#Botanix is pleased to share that an article featuring sofpironium topical gel, 12.45% (Sofdra) appears in the July 2025 issue of the peer-reviewed Journal of the American Academy of Dermatology (JAAD). The article presents pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies that formed the basis for US Food and Drug Administration approval of Sofdra.
Click here to read the article.
